LCLaurent Chouchana

Laurent Chouchana

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Laurent Chouchana has a total of 444 co-authors. Here are the top co-authors by number of shared publications:

  • Jean-Marc Treluyer

    Department of Clinical Pharmacology Cochin Hospital Paris Ile‐de‐France France

    21 shared publications
  • Jean-Marc Treluyer

    Centre Régional de Pharmacovigilance, Service de Pharmacologie périnatale, pédiatrique et adulte, Hopital Cochin, Assistance Publique-Hopitaux de Paris (AP-HP), Paris, France; Université Paris Cité, INSERM UMR-S 1343, Pharmacologie et évaluations des thérapeutiques chez l'enfant et la femme enceinte, F-75006 Paris, France

    15 shared publications
  • Marie-Anne Loriot

    Laboratoire de biochimie, pharmacogénétique et oncologie moléculaire, hôpital européen Georges-Pompidou, 75908 Paris, France

    12 shared publications
  • Benjamin Terrier

    Service de Médecine Interne, Hôpital Cochin, Paris, France

    7 shared publications
  • Camille Mettler

    Service de Médecine Interne, Centre de Référence des maladies auto-immunes systémiques rares d'Ile de France, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France

    7 shared publications
  • Antoine Neuraz

    Department of biomedical informatics, Hôpital Necker-Enfants Malade, Assistance Publique Hôpitaux de Paris (APHP), University of Paris, Paris, France

    6 shared publications

Latest Publications

  • Open Access

    Mental health safety profile of CFTR modulators in pediatrics and adults: insights from the French pharmacovigilance database and from VigiBase

    by Diane A Merino, Samuel D Cohen, Nouha Ben Othman, Marie-Noëlle Osmont, Tessa Pietri, Sandrine Bergeron, Sophie Gautier, Fanny Rocher, Milou-Daniel Drici, Pierre-Régis Burgel, et al.

    Rationale: CFTR modulators (CFTRms) have transformed cystic fibrosis care, yet concern exists regarding their mental health safety profile. Objective: To provide further information, we conducted an analysis of CFTRm-related mental health disorders using two spontaneous pharmacovigilance reporting databases in real-world settings. Methods: We analyzed reports from the French Pharmacovigilance Database (FPD) and VigiBase, the WHO global individual case safety reports database. Reports recorded between 2012 and 2024 involving any CFTRm and psychiatric disorders were included. In VigiBase, we conducted a case-non case, disproportionality analysis using the Reporting Odds Ratio (ROR), overall and stratified by age group (pediatrics vs. adults) and by CFTRm type. This study was conducted in accordance with the STROBE and the READUS-PV guidelines. Results: In the FPD, 116 cases were analyzed. ELX/TEZ/IVA was suspected in 98% of cases and no single case was reported with ivacaftor alone. Sleep (61%), mood (37%), and anxiety disorders (27%) were the most frequently reported, with suicidal behaviors being infrequent, including 6 suicide attempts and no completed suicide. In VigiBase (n = 3,407), sleep disorders predominated in children, whereas mood and suicidality disorders were most frequent in adolescents. The median time to onset was 60 days (Q1-Q3: 12—150 days). Mental health disorders were disproportionately reported with CFTRms, particularly ELX/TEZ/IVA, while they were not with other combination therapies, compared to other drugs in the database. Disproportionality signals were slightly stronger in pediatrics than in adults. Conclusions: CFTRms, especially ELX/TEZ/IVA, are associated with increased reporting of mental health disorders, predominantly sleep and mood disorders. Pediatrics appear to be particularly affected. Prospective observational studies are warranted to confirm these findings and elucidate underlying pathophysiological mechanisms. Registration: OSF: mfyx3

  • Open Access

    Paediatric clonidine medication errors: Findings from a multicentre French study

    by Eve‐Marie Thillard, Anthony Facile, Marion Lepelley, Morgane Cellier, Laurent Chouchana, Sophie Gautier, Ramy Azzouz, Thierry Vial, Annie‐Pierre Jonville‐Bera

    Aims: This study aimed to describe the characteristics of medication errors involving clonidine in paediatric patients and reported to French Network of Pharmacovigilance and Poison Control Centres. Methods: This retrospective observational study analysed clonidine‐related medication errors reported between 1985 and June 2024 in patients under 12 years. Data were extracted from both the French Pharmacovigilance and Poison Control Centres databases. Descriptive statistics were applied to identify common patterns and risk factors. Results: A total of 91 cases were analysed. Most errors occurred during the administration stage in hospital settings (73%). Overexposure exceeding 10 times the prescribed dose was the most frequent (52%), often resulting from the erroneous adaptation of adult formulations for paediatric use. Among 87 cases of overexposure, 41 children (47%) received preventive interventions (e.g., activated charcoal) and 63 (72%) experienced clinical manifestations such as bradycardia, hypotension or somnolence. Among them, 20 (32%) received curative treatment such as fluid support ( n = 10; 50%), atropine ( n = 6; 30%) and naloxone ( n = 6; 30%) administration. Challenges in weight‐based dosing and the lack of paediatric‐specific formulations were identified as significant contributors to errors. Conclusions: Medication errors involving clonidine in paediatric patients are predominantly linked to challenges during hospital administration, exacerbated by the absence of paediatric formulations. Addressing these risks requires regulatory changes, including the development of ready‐to‐use paediatric formulations and standardized dosing protocols, to enhance clonidine safety in clinical practice.

  • Open Access

    Analyse des caractéristiques et de la performance de la nouvelle docimologie au cours des épreuves dématérialisées nationales d’entraînement inter-facultaires du 2e cycle des études médicales

    by Jérôme Hadjadj, Laurent Chouchana, Emmanuel Babin, Louise Basmaciyan, Claire Bonneau, Jean-David Bouaziz, Nathalie Costedoat-Chalumeau, Nicolas De Prost, Jean-Paul Fournier, Florence Jeny, et al.

  • Open Access

    Trends and Characteristics of Opioid Use During Pregnancy Between 2010 and 2023: A French Nationwide Drug Utilization Study

    by Laurent Chouchana, Philippe Herlemont, Hugo Jourdain, Sara Miranda, Mahmoud Zureik, Rosemary Dray‐Spira

    Background: While opioid use during pregnancy has raised concerns worldwide, population‐based data in Europe remain limited. In France, little is known about opioid use in the context of pregnancy. Methods: We conducted a nationwide drug utilization study using the French EPI‐MERES Registry, derived from the National Health Data System (SNDS), including pregnancies ≥ 22 weeks from 2010 to 2023. Exposure to weak and strong opioids was assessed before, during and after pregnancy, and according to calendar years. Exposure characteristics included the number of dispensations, prescriber type and oral morphine equivalents. Maternal sociodemographic and clinical characteristics associated with opioid exposure were analysed using multivariable logistic regression models. Results: Among 9.9 million pregnancies, 548,881 (5.5%) were exposed to weak opioids and 12,501 (0.13%) to strong opioids. Weak opioid exposure increased sharply until 2016 (+120%) before stabilizing; diverging trends were observed thereafter: codeine exposure declined to 3.6% in 2023, whereas tramadol exposure continued to rise (+170% during study period) reaching 2.5%. Opioid exposure substantially decreased after conception and remained low throughout pregnancy. Weak opioid prescriptions were not refilled across trimesters in 85%–95% of exposed pregnancies. Opioid exposure was positively associated with maternal socioeconomic deprivation, chronic diseases and psychiatric disorders, with stronger associations observed for strong opioids. Conclusion: In France, opioid use in the context of pregnancy is not infrequent and almost exclusively driven by short‐term use of weak opioids. It is strongly associated with maternal vulnerability and low‐income status. Although overall opioid exposure stabilized since 2016, the continuous rise in tramadol use warrants further monitoring. Significance: Population‐based evidence on opioid use during pregnancy is scarce in Europe and has been lacking in France. This nationwide study provides the first comprehensive analysis of prescription opioid use in pregnancy in France over a 14‐year period, identifying prescribing patterns and populations most likely to be exposed. After a marked increase at the beginning of the study period, overall opioid exposure is stable. In the most recent years, one in 16 pregnant women is exposed to an opioid, almost exclusively a weak opioid, and we observed a sustained rise in tramadol exposure throughout the study period. These findings establish a benchmark for future surveillance.

  • Open Access

    Maternal and Neonatal Complications Associated with Breast Cancer Systemic Treatments—A VigiBase Disproportionality Analysis Study

    by Rayan Kabirian, Floriane Jochum, Elise Dumas, Florence Coussy, Kevin Bihan, Bénédicte Lebrun‐Vignes, Barbara Pistilli, Marc‐Antoine Benderra, Lise Selleret, Laurent Chouchana, et al.

    Pregnancy‐associated breast cancer (PrBC) presents therapeutic challenges. Understanding maternal–fetal safety of systemic anticancer therapies is critical. We performed a case/non‐case disproportionality analysis using the WHO global pharmacovigilance database up to January 2024, to evaluate maternal–fetal outcomes associated with breast cancer (BC) systemic treatments. The exposure group consisted of reports mentioning a BC treatment at any time during pregnancy. The primary outcome was the reporting odds ratio (ROR) of maternal–fetal complications with the two cornerstone cytotoxic classes, anthracyclines (doxorubicin, epirubicin) and taxanes (docetaxel, paclitaxel), assessed individually vs. other anticancer treatments. Secondary analyses assessed all BC treatments and trimester‐specific risks. Of 3310 pregnancy‐related reports, 1789 involved BC treatments. Median maternal age was 27.4 years (SD 13.8) vs. 29.3 (SD 11.7) in the comparator group. Adverse maternal–fetal outcomes were reported in 998 (55.8%) BC treatment reports vs. 470 (30.9%) in other anticancer treatments. Anthracyclines were associated with neonatal hematologic disorders (ROR = 1.7, 95% CI = 1.1–2.5) and intrauterine growth restriction (IUGR) (ROR = 2.1, 95% CI = 1.7–2.7). Paclitaxel was linked to sensory defects including congenital ear/ocular anomalies (ROR = 5.2, 95% CI = 2.2–12.3); all 8 cases involved platinum co‐exposure (cisplatin: n = 5; carboplatin: n = 3), suggesting a platinum‐mediated mechanism; and to hyperbilirubinemia (ROR = 4.1, 95% CI = 2.0–8.4), and docetaxel to neonatal neurologic disorders (ROR = 3.6, 95% CI = 1.4–9.3). First‐trimester exposure ( n = 26) showed preliminary signals of increased congenital malformation risk, including face (ROR = 13, 95% CI = 2–79), and musculoskeletal malformation (ROR = 8, 95% CI = 1.1–60). This pharmacovigilance study identifies signals of disproportionate reporting of specific maternal and neonatal outcomes with BC treatments; these findings are hypothesis‐generating and require confirmation in prospective registries.


  • Open Access

    A descriptive case series of hepatotoxicity associated with CFTR modulators and possible relevance of pharmacogenetic polymorphisms in cystic fibrosis patients

    by Clara Laffitte Redondo, Venceslas Bourdin, Abd El Kader Ait Tayeb, Sihem Benaboud, Inès Martins, Caroline Joyau, Myriam Benhamida, Isabelle Sermet‐Gaudelus, Clémence Martin, Pierre Régis Burgel, et al.

    Cystic fibrosis transmembrane conductance regulator (CFTR) modulators are widely used in patients with cystic fibrosis and significantly improve respiratory function and quality of life. However, their effectiveness may be limited by liver damage, which sometimes leads to treatment discontinuation, and the mechanisms underlying this remain poorly understood. This case series explores the role of genetic polymorphisms affecting the enzymes and transporters involved in their pharmacokinetics, as well as detoxification mechanisms (CYP3A4/CYP3A5/ABCB1/SLCO1B1/GSTP1/GSTM1/GSTT1). Six cases of hepatotoxicity under CFTR modulators were assessed using the RECAM score. Among the genetic polymorphisms assessed, CYP3A4*22 (rs35599367) allele had higher allele frequency than in the European population, which usually does not express CYP3A5. This genetic variant, reducing CYP3A activity, could decrease the elimination of CFTR modulators and increase the risk of liver toxicity. Other genetic factors may also be involved. Further studies are needed to confirm these results.

  • Optimisation de la réponse aux thiopurines par la pharmacogénétique : approches in vitro et cliniques

    by Laurent Chouchana

    Les thiopurines sont des médicaments cytotoxiques et immunosuppresseurs largement prescrits, notamment dans les maladies inflammatoires chroniques de l’intestin (MICI). Ils représentent l’un des meilleurs exemples d’application clinique de la pharmacogénétique avec le dépistage du déficit en thiopurine S-méthyltransférase (TPMT), enzyme clé du métabolisme des thiopurines. La variabilité interindividuelle de la réponse à ces médicaments rend nécessaire leur optimisation thérapeutique. Ce travail de thèse a d’une part, analysé les relations entre activité TPMT et concentrations des métabolites thiopuriniques, et d’autre part, recherché des facteurs associés à la résistance aux thiopurines. A l’aide d’une base de données pharmacogénétiques hospitalière et d’une étude « PheWAS » à partir d’un entrepôt de données cliniques, nous avons analysé la distribution et la corrélation génotype-phénotype pour la TPMT, en lien avec les concentrations des métabolites thiopuriniques. Nous avons observé qu’une activité TPMT très élevée (phénotype « ultra-rapide ») était associée à des paramètres clinico-biologiques reflétant une maladie évolutive et un traitement inefficace dans les MICI. De plus, une étude clinique rétrospective dans les MICI pédiatriques a permis d’identifier des facteurs associés à la lymphopénie observée sous thiopurines. Enfin, à partir d’un modèle in vitro fondé sur des lignées cellulaires lymphoblastoïdes (LCL) sélectionnées, nous avons établi une signature transcriptomique, incluant 32 gènes, prédictive de la résistance aux thiopurines. Une analyse fonctionnelle bioinformatique a abouti à l’identification de voies métaboliques liées à la protéine p53 et au cycle cellulaire, ainsi que des mécanismes moléculaires associés à la résistance aux thiopurines. En conclusion, ce travail de thèse, qui a exploré la variabilité de réponse aux thiopurines et tout particulièrement la résistance à ces médicaments, propose des hypothèses pour l’individualisation et l’optimisation thérapeutique des thiopurines.

  • Trends of Opioids and Nefopam Use Among French Children: A Population-Based Study From 2009 to 2023

    by Sandrella Hamdan, Pierre Pinson, Jean-Marc Tréluyer, Florentia Kaguelidou, Laurent Chouchana, Violaine Smail-Faugeron

    Background and objectives Effective pain management in children is a public health priority, while opioid-related risks remain a major concern. The aim of the present study was to describe trends of opioids and nefopam use in children in France. Methods We conducted a nationwide drug utilization study using the French National Health Data System (SNDS), covering > 98% of the French population. All children with at least one prescription for a weak opioid, strong opioid, or nefopam between 2009 and 2023 were included. Annual prevalence of use was estimated per 1000 children, stratified by age group (< 2, 2–6, 7–11, 12–17 years). Joinpoint regression was used to analyze temporal trends. Contraindicated use was defined according to age restrictions in marketing authorizations. Results Overall, 4,443,648 children were included in the study. Overall prevalence of analgesic use increased from 22.7‰ in 2009 to 27.4‰ in 2023, mainly driven by weak opioids (26.3‰ in 2023). In 2023, tramadol was the most prescribed weak opioid (13.5‰), followed by codeine (10.1‰). Nefopam use, contraindicated for use under 15 years of age, rose sharply to 1.9‰. Strong opioids, notably morphine and oxycodone, steadily increased but remained low (0.4‰ and 0.08‰, respectively). Most children receiving prescriptions were aged 12–17 years, although weak opioid use declined in this group over the study period. In contrast, children aged 2–6 years showed a fivefold increase in overall analgesic use, driven almost entirely by tramadol, which increased eightfold, while codeine use declined. Contraindicated use remained frequent for tramadol, codeine, opium powder, and nefopam, increasing as children approached the minimal approved age. Conclusion Tramadol was the most commonly prescribed opioid used in pediatric outpatients in France in 2023, followed by codeine. Tramadol off-label use steadily increased, whereas codeine off-label use decreased. The sharp rise in tramadol, especially in children aged 2–6 years, and nefopam prescribing, together with increasing morphine and oxycodone use, in association with frequent contraindicated use, underscores the need for enhanced surveillance and pediatric-specific safety data.